Trump’s Executive Order on Drug Prices
Washington: US President Donald Trump has signed an executive order aimed at reducing drug prices in the United States, aligning them with prices overseas. The order sets a 30-day deadline for pharmaceutical companies to meet specified price targets, with the promise of further actions if significant progress isn’t made.
Trump expressed his intention to slash drug prices by at least 59%, emphasizing his belief that everyone should pay the same rate for medications. He criticized the European Union for what he described as “brutal” tactics, suggesting that US drug prices are inflated because companies raise them to profit from American consumers.
As part of the initiative, the US plans to implement a “most favored nation” policy that would ensure drug prices in the US reflect the lowest prices offered by other nations. Trump noted that, despite the US representing only 4% of the global population, pharmaceutical companies generate over two-thirds of their profits there.
He further claimed that American consumers have been treated unfairly, referencing the high cost of the drug Ozempic, used for obesity treatment. He relayed a conversation with an unnamed friend who shared that this medication costs $88 in London, whereas it’s priced at $1,300 in the US.
US Drug Pricing Context
The United States consistently pays the highest prices for prescription medications among developed nations, often nearly three times higher than in other countries. Trump had previously attempted to align US prices with those elsewhere during his first term, but those efforts faced legal hurdles.
Implementing this new plan will depend largely on the willingness of pharmaceutical companies to negotiate, likely subject to legal challenges similar to those faced in his first term. The proposal aims to address inflation and make various everyday items more affordable for Americans.
Details of Trump’s Order
Should drug manufacturers fail to meet the government’s expectations, the Trump administration may explore implementing international pricing and drug imports from other developed countries, among other measures. The order also instructed the government to consider direct purchasing programs for consumers to access medication at international prices and directed the Federal Trade Commission to enhance enforcement against what it identifies as anti-competitive practices by drugmakers.
Potential Challenges
Legal challenges are anticipated concerning the executive orders, particularly regarding their adherence to US laws on drug imports. Critics like Kim argue that proposals for direct import of drugs exceed legal boundaries.
However, health law expert Lawrence Gostin from Georgetown Law posits that any legal opposition may arise only after the administration takes more tangible steps towards lowering prices rather than just issuing threats. He noted that once companies are required to reduce drug prices, it could trigger a wave of lawsuits.
The Federal Trade Commission has a long-standing record of taking antitrust actions against pharmaceutical and healthcare companies. Recently, Trump directed the FTC to collaborate with other federal agencies and initiated discussions on anti-competitive behaviors within the pharmaceutical sector.
FTC spokesman Joe Simonson stated, “President Donald Trump has campaigned on reducing drug costs, and today he is doing just that. Americans are tired of being taken advantage of. The Federal Trade Commission will be a proud partner in this new effort.”
